Benign Prostatic Hyperplasia: A New Metabolic Disease of the Aging Male and Its Correlation with Sexual Dysfunctions
Figure 3
Weighted differences (with 95% confidence interval (CI)) of International Prostate Symptom Score (IPSS; (a)) and maximum flow rate (; (b)), for the studies on phosphodiesterase type 5 inhibitors (PDE5-Is) versus placebo. § no erectile dysfunction; §§ erectile dysfunction.
